These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38354138)

  • 1. Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
    Vermersch P; Granziera C; Mao-Draayer Y; Cutter G; Kalbus O; Staikov I; Dufek M; Saubadu S; Bejuit R; Truffinet P; Djukic B; Wallstroem E; Giovannoni G;
    N Engl J Med; 2024 Feb; 390(7):589-600. PubMed ID: 38354138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
    Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X; Arnold DL; Weber MS; Staikov I; Piasecka-Stryczynska K; Willmer J; Martin EC; Dangond F; Syed S; Wolinsky JS;
    N Engl J Med; 2019 Jun; 380(25):2406-2417. PubMed ID: 31075187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
    Segal BM; Constantinescu CS; Raychaudhuri A; Kim L; Fidelus-Gort R; Kasper LH;
    Lancet Neurol; 2008 Sep; 7(9):796-804. PubMed ID: 18703004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
    Steinman L; Fox E; Hartung HP; Alvarez E; Qian P; Wray S; Robertson D; Huang D; Selmaj K; Wynn D; Cutter G; Mok K; Hsu Y; Xu Y; Weiss MS; Bosco JA; Power SA; Lee L; Miskin HP; Cree BAC;
    N Engl J Med; 2022 Aug; 387(8):704-714. PubMed ID: 36001711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
    Hauser SL; Waubant E; Arnold DL; Vollmer T; Antel J; Fox RJ; Bar-Or A; Panzara M; Sarkar N; Agarwal S; Langer-Gould A; Smith CH;
    N Engl J Med; 2008 Feb; 358(7):676-88. PubMed ID: 18272891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Miller DH; Weber T; Grove R; Wardell C; Horrigan J; Graff O; Atkinson G; Dua P; Yousry T; Macmanus D; Montalban X
    Lancet Neurol; 2012 Feb; 11(2):131-9. PubMed ID: 22226929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
    Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
    N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
    Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
    Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
    Hemmer B; Wiendl H; Roth K; Wessels H; Höfler J; Hornuss C; Liedert B; Selmaj K
    JAMA Neurol; 2023 Mar; 80(3):298-307. PubMed ID: 36689214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
    Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J;
    Lancet Neurol; 2014 Apr; 13(4):353-63. PubMed ID: 24613349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
    BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocrelizumab for multiple sclerosis.
    Lin M; Zhang J; Zhang Y; Luo J; Shi S
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
    Boyko AN; Alifirova VM; Lukashevich IG; Goncharova ZA; Greshnova IV; Zaslavsky LG; Kotov SV; Malkova NA; Mishin GN; Parshina EV; Poverennova IY; Prakhova LN; Sivertseva SA; Smagina IV; Totolyan NA; Trinitatsky YV; Trushnikova TN; Khabirov FA; Chefranova JY; Shchur SG; Dudin VA; Pokhabov DV; Artemeva AV; Eremeeva AV; Linkova YN; Zinkina-Orikhan AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4):86-96. PubMed ID: 38676683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.
    Kappos L; Arnold DL; Bar-Or A; Camm J; Derfuss T; Kieseier BC; Sprenger T; Greenough K; Ni P; Harada T
    Lancet Neurol; 2016 Oct; 15(11):1148-59. PubMed ID: 27543447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
    Radue EW; Sprenger T; Vollmer T; Giovannoni G; Gold R; Havrdova E; Selmaj K; Stefoski D; You X; Elkins J
    Eur J Neurol; 2016 Feb; 23(2):412-5. PubMed ID: 26806217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.